Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2026)

Vanda Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 13.73% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.1 million (down 23.29% YoY), while the FY2025 annual figure was $9.5 million, down 23.79% from the prior year.
• Share-based Compensation came in at $2.6 million for Q1 2026 at Vanda Pharmaceuticals, up from $2.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.8 million in Q1 2022 to a low of $2.1 million in Q2 2025.
• A 5-year average of $3.2 million and a median of $3.2 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation rose 22.23% in 2022 and dropped 29.58% in 2025, its largest moves.
• Vanda Pharmaceuticals' Share-based Compensation stood at $3.8 million in 2022, then decreased by 13.48% to $3.3 million in 2023, then retreated by 12.53% to $2.9 million in 2024, then retreated by 20.19% to $2.3 million in 2025, then grew by 12.17% to $2.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.6 million, $2.3 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison